Osteoarthritis, a disease that causes severe joint pain, affects more than 20 million people in the United States. Some drug treatments can help alleviate the pain, but there are no treatments that can reverse or slow the cartilage breakdown associated with the disease.
In an advance that could improve the treatment options available for osteoarthritis, MIT engineers have designed a new material that can administer drugs directly to the cartilage. The material can penetrate deep into the cartilage, delivering drugs that could potentially heal damaged tissue.
“This is a way to get directly to the cells that are experiencing the damage, and introduce different kinds of therapeutics that might change their behavior,” says Paula Hammond, head of MIT’s Department of Chemical Engineering, a member of MIT’s Koch Institute for Integrative Cancer Research, and the senior author of the study.
In a study in rats, the researchers showed that delivering an experimental drug called insulin-like growth factor 1 (IGF-1) with this new material prevented cartilage breakdown much more effectively than injecting the drug into the joint on its own.
Brett Geiger, an MIT graduate student, is the lead author of the paper, which appears in the Nov. 28 issue of Science Translational Medicine. Other authors are Sheryl Wang, an MIT graduate student, Robert Padera, an associate professor of pathology at Brigham and Women’s Hospital, and Alan Grodzinsky, an MIT professor of biological engineering.
Osteoarthritis is a progressive disease that can be caused by a traumatic injury such as tearing a ligament; it can also result from gradual wearing down of cartilage as people age. A smooth connective tissue that protects the joints, cartilage is produced by cells called chondrocytes but is not easily replaced once it is damaged.
Previous studies have shown that IGF-1 can help regenerate cartilage in animals. However, many osteoarthritis drugs that showed promise in animal studies have not performed well in clinical trials.
The MIT team suspected that this was because the drugs were cleared from the joint before they could reach the deep layer of chondrocytes that they were intended to target. To overcome that, they set out to design a material that could penetrate all the way through the cartilage.
The sphere-shaped molecule they came up with contains many branched structures called dendrimers that branch from a central core. The molecule has a positive charge at the tip of each of its branches, which helps it bind to the negatively charged cartilage. Some of those charges can be replaced with a short flexible, water-loving polymer, known as PEG, that can swing around on the surface and partially cover the positive charge. Molecules of IGF-1 are also attached to the surface.
When these particles are injected into a joint, they coat the surface of the cartilage and then begin diffusing through it. This is easier for them to do than it is for free IGF-1 because the spheres’ positive charges allow them to bind to cartilage and prevent them from being washed away. The charged molecules do not adhere permanently, however. Thanks to the flexible PEG chains on the surface that cover and uncover charge as they move, the molecules can briefly detach from cartilage, enabling them to move deeper into the tissue.
“We found an optimal charge range so that the material can both bind the tissue and unbind for further diffusion, and not be so strong that it just gets stuck at the surface,” Geiger says.
Once the particles reach the chondrocytes, the IGF-1 molecules bind to receptors on the cell surfaces and stimulate the cells to start producing proteoglycans, the building blocks of cartilage and other connective tissues. The IGF-1 also promotes cell growth and prevents cell death.
When the researchers injected the particles into the knee joints of rats, they found that the material had a half-life of about four days, which is 10 times longer than IGF-1 injected on its own. The drug concentration in the joints remained high enough to have a therapeutic effect for about 30 days. If this holds true for humans, patients could benefit greatly from joint injections — which can only be given monthly or biweekly — the researchers say.
In the animal studies, the researchers found that cartilage in injured joints treated with the nanoparticle-drug combination was far less damaged than cartilage in untreated joints or joints treated with IGF-1 alone. The joints also showed reductions in joint inflammation and bone spur formation.
“This is an important proof-of-concept that builds on the recent advances in the identification of anabolic growth factors with clinical promise (such as IGF-1), with promising disease-modifying results in a clinically relevant model. Delivery of growth factors using nanoparticles in a manner that sustains and improves treatments for osteoarthritis is a significant step for nanomedicines,” says Kannan Rangaramanujam, a professor of ophthalmology and co-director of the Center for Nanomedicine at Johns Hopkins School of Medicine, who was not involved in the research.
Cartilage in rat joints is about 100 microns thick, but the researchers also showed that their particles could penetrate chunks of cartilage up to 1 millimeter — the thickness of cartilage in a human joint.
“That is a very hard thing to do. Drugs typically will get cleared before they are able to move through much of the cartilage,” Geiger says. “When you start to think about translating this technology from studies in rats to larger animals and someday humans, the ability of this technology to succeed depends on its ability to work in thicker cartilage.”
The researchers began developing this material as a way to treat osteoarthritis that arises after traumatic injury, but they believe it could also be adapted to treat age-related osteoarthritis. They now plan to explore the possibility of delivering different types of drugs, such as other growth factors, drugs that block inflammatory cytokines, and nucleic acids such as DNA and RNA.
The Latest on: Osteoarthritis
via Google News
The Latest on: Osteoarthritis
- Arthritis Researchers Develop New Way to Identify Osteoarthritis Severityon October 14, 2021 at 9:37 pm
CNW/ - Arthritis Canada scientists have created a new grading scale to measure the severity of osteoarthritis in patients. "This scale is unique because it measures cartilage damage, the presence of ...
- Antibe Therapeutics Provides Update on Otenaproxesul and Expanded Drug Pipelineon October 14, 2021 at 4:00 am
New patent application aimed at extending otenaproxesul’s IP protection into the 2040s - Dosing regimen for osteoarthritis indication requires additional investigation TORONTO, October 14, 2021 -- ( ...
- Pacira to Buy Flexion, Boosting Pain Management Portfolioon October 13, 2021 at 11:46 am
The deal involves multiple milestones, including the initiation of a phase 3 trial of Zilretta in shoulder osteoarthritis.
- Varian wins FDA breakthrough nod for microspheres that treat knee osteoarthritison October 13, 2021 at 11:41 am
Varian announced today that it received FDA breakthrough device designation for its Embozene microspheres for treating knee osteoarthritis.
- Topical pain-killers more effective, safer than opioids for knee osteoarthritis painon October 13, 2021 at 6:21 am
Topical medication for pain relief is safer and more effective than opioids in treating knee osteoarthritis pain, according to a meta-analysis by Unity Health Toronto researchers.
- Varian Receives FDA "Breakthrough Device Designation" For Embozene Microspheres For Genicular Artery Embolization For Symptomatic Knee Osteoarthritison October 13, 2021 at 6:00 am
Varian, a Siemens Healthineers company, announced today that the U.S. Food and Drug Administration (FDA) has granted the company Breakthrough Device Designation for its Embozene ® microspheres for ...
- How athletes can deal with osteoarthritis of the kneeson October 12, 2021 at 4:05 am
Does osteoarthritis of the knee mean the end of your running days? Our resident Physio Paul Hobrough says perhaps not ...
- Global Osteoarthritis Medications Market 2021 Key Players, SWOT Analysis, Key Indicators, Forecast and COVID-19 Impact Analysis 2027on October 10, 2021 at 1:18 pm
Major companies holding significant market shares in the global Osteoarthritis Medications market are analyzed considering their market revenue, market shares, business strategies, recent developments ...
- Smoking, Obesity Increase Risk for Trajectories of Depression and Comorbidities in Patients With Knee Osteoarthritison October 6, 2021 at 11:11 am
Researchers identified trajectories of depression and comorbidity in patients with knee osteoarthritis, and described the characteristics of distinctive trajectories.
via Bing News